Ascentage Pharma, a leading biopharmaceutical company, has presented encouraging clinical data on the MDM2-p53 inhibitor alrizomadlin (APG-115) at the 61st ASCO Annual Meeting. This Phase II study evaluated the efficacy of alrizomadlin as a monotherapy or in combination with the PD-1 inhibitor toripalimab in patients with advanced adenoid cystic carcinoma (ACC) and other solid tumors. Alrizomadlin, a novel drug in Ascentage Pharma’s apoptosis-targeted pipeline, showcases global first-in-class potential as the first MDM2-p53 inhibitor undergoing clinical development in China.
Read more from bakersfield.com
